Clinical Trial Update: Evaluation of the Risk of NSF Following ProHance Injection in Patients With Chronic Kidney Disease

View source ↗

Summary

This completed study evaluated the risk of nephrogenic systemic fibrosis after injecting ProHance in people with chronic kidney disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• PROHANCE (GADOTERIDOL)

Snippet

Sponsor: Bracco Diagnostics, Inc | Conditions: Renal Insufficiency | Status: COMPLETED